CompanyAMRNNasdaqDublin 2

Amarin Corp Plc\Uk

Amarin develops icosapent ethyl for cardiovascular disease.

SEC EDGAR ClinicalTrials.gov amarincorp.com

8-KOct 1Latest SEC filing

Jul 29Latest story

July 2026

Amarin posts Q2 2026 results as international partner sales grow, US expenses fall

Jul 29Quarterly updateAmarin Corp Plc\Uk icosapent ethyl